Cytokine storm after cessation of tocilizumab in a patient with refractory Takayasu arteritis-Reference-Cited by-同舟云学术

Cytokine storm after cessation of tocilizumab in a patient with refractory Takayasu arteritis

Published:2015-05 Issue: Volume:187 Page:319-321
ISSN:0167-5273
Container-title:International Journal of Cardiology
language:en
Short-container-title:International Journal of Cardiology

Author:

Arita Yoh,Nakaoka Yoshikazu,Otsuki Michio,Higuchi Kaori,Hashimoto-Kataoka Takahiro,Yasui Taku,Masaki Takeshi,Ohtani Tomohito,Kishimoto Tadamitsu,Yamauchi-Takihara Keiko,Komuro Issei,Sakata Yasushi

Funder

Ministry of Health, Labor, and Welfare of Japan

Translational Research Promotion Program of Japanese Circulation Society

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference10 articles.

1. Takayasu arteritis revisited: current diagnosis and treatment;Isobe;Int. J. Cardiol.,2013

2. EULAR recommendations for the management of large vessel vasculitis;Mukhtyar;Ann. Rheum. Dis.,2009

3. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients;Maksimowicz-McKinnon;Arthritis Rheum.,2007

4. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody;Nishimoto;Arthritis Rheum.,2008

5. Tocilizumab: a novel therapy for patients with large-vessel vasculitis;Salvarani;Rheumatology,2012

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Immunosuppressive Treatment for Takayasu Arteritis;Circulation Journal;2023-12-19

2. Autoimmune Heart Disease: A Comprehensive Summary for Forensic Practice;Medicina;2023-07-25

3. Comment on: Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study: reply;Rheumatology;2020-06-28

4. Takayasu arteritis - epidemiology, pathogenesis, diagnosis and treatment;Journal of Applied Biomedicine;2019-03-19

5. Pathophysiology of large vessel vasculitis and utility of interleukin-6 inhibition therapy;Modern Rheumatology;2019-02-04